Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is under...
Main Authors: | Maxton E. Thoman, Susan C. McKarns |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/10/9/374 |
Similar Items
-
Sera of Neuromyelitis Optica Patients Increase BID-Mediated Apoptosis in Astrocytes
by: Omri Zveik, et al.
Published: (2022-06-01) -
Familial Neuromyelitis Optica: A Case Report and Literature Review
by: zahra ebadi, et al.
Published: (2023-03-01) -
The circadian rhythms regulated by Cx43-signaling in the pathogenesis of Neuromyelitis Optica
by: Huiru Xue, et al.
Published: (2023-01-01) -
Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G
by: Xiaoming Yao, et al.
Published: (2017-07-01) -
Pediatric Neuromyelitis Optica Spectrum Disorders: Three Case Reports and Review of Literature
by: Seyed Mohammad Baghbanian, et al.
Published: (2020-04-01)